Doximity Inc
NYSE:DOCS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Doximity Inc
NYSE:DOCS
|
US |
|
Actinium Pharmaceuticals Inc
F:7AY1
|
US |
|
Red Cat Holdings Inc
F:BQ73
|
PR |
|
M
|
Magnum Ice Cream Company NV
AEX:MICC
|
NL |
|
A
|
AnorTech Inc
LSE:0V0E
|
CA |
|
M
|
Mobico Group PLC
DUS:3NA
|
UK |
|
J
|
Jentayu Sustainables Bhd
KLSE:JSB
|
MY |
|
Dovalue SpA
F:1DB0
|
IT |
|
E
|
Econframe Bhd
KLSE:EFRAME
|
MY |
|
S
|
Somnigroup International Inc
NYSE:SGI
|
US |
|
P
|
Pt Astrindo Nusantara Infrastruktur Tbk
SWB:J9B
|
ID |
|
D
|
Danavation Technologies Corp
OTC:DVNCF
|
CA |
|
G
|
Greenrise Global Brands Inc
SWB:C4T
|
CA |
|
H
|
Harbour-Link Group Bhd
KLSE:HARBOUR
|
MY |
|
M
|
MFC Asset Management PCL
SET:MFC
|
TH |
Earnings Calls
Last Earnings Call
Beat and raise: Doximity reported Q1 revenue of $157 million, up 7% year over year, and adjusted EBITDA of $75 million, both ahead of the high end of guidance. Management raised full-year revenue guidance by $6 million and lifted EBITDA guidance as AI spending steps up.
AI momentum: Usage of Doximity’s clinical AI tools is growing fast, with quarterly active workflow prescribers up more than 30% and AI prompt volume up more than 25% quarter over quarter.
Study win: Management leaned heavily on the NOHARM study, saying Doximity Ask delivered the lowest clinical error rates and highest safety ratings among U.S. models in the independent comparison.
Commercial traction: AI search is already helping open new conversations with pharma and hospital customers, and management said the majority of contracted AI search revenue will be recognized in Q3.
Investment year: The company said fiscal 2027 is an AI investment year, with higher compute and operating spend planned to support faster usage and future monetization.